Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00161434 · ClinicalTrials.gov registry record · Phase 4
A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons
A Phase 4 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT00161434 is a Phase 4 study that has completed, run by University of Washington. The registered enrollment target is 60 participants.
The verdict
NCT00161434, a Phase 4 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary objective of this research study is to assess if daily valacyclovir therapy for suppression of HSV-2 reactivation is associated with a decrease in mucosal HIV shedding in individuals co-infected with both HSV-2 and HIV.
Interventions
- DRUG placebo
- DRUG valacyclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-03 |
| Est. Completion | 2006-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00161434
The ClinicalTrials.gov registry entry for NCT00161434 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00161434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00161434 about?
NCT00161434 is a clinical study titled "A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons". The primary objective of this research study is to assess if daily valacyclovir therapy for suppression of HSV-2 reactivation is associated with a decrease in mucosal HIV shedding in individuals co-infected with both HSV-2 and HIV.
What is the current status of trial NCT00161434?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2003-03. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00161434?
The interventions under investigation include: placebo (DRUG), valacyclovir (DRUG).
Who is sponsoring clinical trial NCT00161434?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.